Tesamorelin/Ipamorelin Stack: Evidence, Mechanism & Status

The tesamorelin/ipamorelin stack pairs a stabilized GHRH analog — tesamorelin, the only FDA-approved GHRH analog — with ipamorelin, a selective ghrelin-receptor (GHS-R1a) agonist, to drive a larger pulse of endogenous growth hormone than either agent alone.48 The combination is heavily marketed for body composition and recovery; its proof as a combination is absent. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. The combination is not an FDA-approved drug; ipamorelin is sold "research use only," and both agents are prohibited in sport at all times. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is the tesamorelin/ipamorelin stack and how does it work?

The two components target two independent receptor systems on the same pituitary somatotroph. Tesamorelin is a 44-amino-acid stabilized analog of human GHRH(1–44), modified with a trans-3-hexenoic acid group on the N-terminus that resists dipeptidyl-peptidase degradation, extending its half-life relative to native GHRH.8 It binds the GHRH receptor, a Gs-coupled GPCR, signaling through the cAMP/PKA pathway to stimulate synthesis and pulsatile release of endogenous GH; downstream hepatic IGF-1 rises, and because visceral adipose tissue has higher GH-receptor density and lipolytic rate than subcutaneous fat, the GH pulse mobilizes visceral fat preferentially.6 Its subcutaneous half-life is roughly 26–38 minutes, producing a discrete pulse that clears and preserves natural pulsatility rather than a sustained "GH bleed."8

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2, MW ~711.9 Da) developed at Novo Nordisk and first characterized by Raun and colleagues.4 It is a growth-hormone secretagogue receptor (GHS-R1a) agonist — a ghrelin mimetic — signaling through the PLC/IP3/intracellular-calcium pathway. Its defining property is selectivity: in conscious swine it released GH with potency comparable to GHRP-6 (ED50 ~2.3 nmol/kg) without the ACTH, cortisol, or prolactin elevation seen with GHRP-6/GHRP-2, even at doses more than 200-fold the GH ED50.4 GHRP/ghrelin agonism also suppresses somatostatin tone, removing the dominant brake on GH release.

The synergy mechanism follows: because the two ligands hit different receptors coupled to different second-messenger systems (cAMP/PKA versus PLC/calcium), simultaneous activation yields GH release that can exceed the sum of the parts — tesamorelin supplies the positive secretory drive while ipamorelin amplifies the somatotroph pulse and lifts the somatostatin brake. This is the same dual-input architecture the hypothalamus uses during deep-sleep GH pulses. In humans the synergy is real and reproducible — co-administration of GHRH plus GHRP-6 produced markedly higher GH than either alone in young and older adults.1 Crucially, it depends on an intact hypothalamic-pituitary connection and is blunted in patients with hypothalamo-pituitary disconnection or macroprolactinoma, recovering only after the lesion is treated.3

What is the evidence by indication?

The honest summary is that the combination has never been tested. The table below separates what each layer of evidence actually supports.

For the marketed combination use there are no published RCTs, cohort studies, or open-label human trials for any endpoint. Clinic and vendor materials claim enhanced fat loss, recovery, and lean-mass support — figures such as "60–75% of users report enhanced outcomes versus monotherapy" — but these are uncontrolled marketing numbers with no primary data behind them.1516 This is Grade D.

For the class mechanism, human pharmacodynamic evidence is strong. In a randomized crossover study, GHRH 100 µg plus GHRP-6 90 µg IV produced significantly greater GH than GHRH alone (F = 21.9, P < 0.001) or GHRP-6 alone (F = 6.2, P = 0.01), with the response preserved in older adults.1 In normal subjects, GHRH plus GHRP-6 drove a peak plasma GH near 76.7 µg/L at 30 minutes.2 This validates the rationale, not the product.

For tesamorelin monotherapy, the evidence is genuinely Grade A. The pivotal RCT randomized 412 HIV-positive adults with lipodystrophy to tesamorelin 2 mg SC daily versus placebo for 26 weeks; visceral fat fell about −10.9% versus −0.6% with placebo.5 A separate double-blind RCT showed reductions in liver fat and visceral fat.6 A 2025 meta-analysis confirmed significant reductions in visceral, trunk, limb, and hepatic fat with an IGF-1 rise and no serious glucose perturbation.7 This Grade-A evidence is for tesamorelin alone in HIV lipodystrophy — not the combination and not the general-wellness population. Readers can verify the labeled indication directly in the FDA Egrifta prescribing information.

What doses appear in the literature?

Reported strictly as information, not a protocol. FDA-labeled tesamorelin monotherapy is 2 mg subcutaneously once daily into the abdomen, reconstituted from lyophilized powder; the newer F8 formulation (Egrifta WR, approved March 2025) requires only weekly reconstitution and a smaller injection volume.89 For the combination, anecdotal compounding-clinic reports cite roughly tesamorelin ~1 mg plus ipamorelin ~200–300 µg subcutaneously once daily, often dosed at night on an empty stomach to align with the natural nocturnal GH pulse and avoid food-induced blunting of the GH response.1716 These figures are not validated by any trial, are not standardized, and originate from vendor and clinic material. Both peptides are supplied lyophilized and reconstituted with bacteriostatic or sterile water; GHRP GH responses are blunted by recent food, glucose, free fatty acids, and glucocorticoids — the pharmacologic reason fasting and nighttime dosing are described.1

How safe is the tesamorelin/ipamorelin stack?

No combination-specific safety dataset exists; the profile below is assembled from tesamorelin's labeled adverse events and GH-secretagogue class effects, and stacking two GH-raising agents could plausibly amplify GH/IGF-1-mediated effects. The most common labeled tesamorelin events are injection-site reactions, arthralgia and myalgia, peripheral edema and fluid retention, paresthesia or carpal-tunnel-type symptoms, and headache.8 Because growth hormone is counter-regulatory, tesamorelin can worsen glucose tolerance, and the label calls for monitoring in patients with or at risk of diabetes; a second secretagogue could compound this.8 Both agents raise GH and therefore IGF-1, which is mitogenic, and the long-term cancer-surveillance consequences of sustained elevation are unknown — active malignancy is a contraindication.8 Roughly half of treated patients developed anti-tesamorelin antibodies, with cross-reactivity to endogenous GHRH in many of them, though efficacy was similar with or without antibodies.8 Ipamorelin's selectivity advantage — no significant ACTH, cortisol, or prolactin rise — is its main theoretical safety edge, but that is animal data; human long-term safety is uncharacterized.4 Contraindications and cautions include pregnancy, active malignancy, acute critical illness, a disrupted hypothalamic-pituitary axis, open epiphyses in children, proliferative diabetic retinopathy, and known hypersensitivity.3

What is the FDA and WADA status in 2026?

The two components sit in very different regulatory positions, and the blend has none of its own. Tesamorelin has been FDA-approved since 2010 as Egrifta, with Egrifta SV and the weekly-reconstitution Egrifta WR (sBLA approved March 25, 2025) — indicated solely for reducing excess abdominal visceral fat in HIV-associated lipodystrophy. All body-composition, longevity, or men's-health use is off-label.89 Ipamorelin is not FDA-approved for any indication. It was placed into 503A Category 2 in September 2023, then — after litigation and a September 2024 settlement — its nomination was withdrawn and it was removed from Category 2, and FDA brought it to an October 2024 PCAC meeting for evaluation toward the 503A bulks rule. As of 2026 the status remains under active, rolling FDA review rather than a final allow-or-deny determination.101112 The blend itself has no FDA approval; co-formulated products are compounded or research-grade, outside the labeled supply chain.

For athletes the picture is unambiguous. Both agents are prohibited at all times — in and out of competition — under Section S2.2 of the WADA Prohibited List: tesamorelin (with sermorelin and the CJC compounds) as a GHRH and analogue, and ipamorelin (with anamorelin, MK-677, and the GHRPs) as a growth-hormone secretagogue or mimetic.1314 Because the prohibition is written at the class level, co-formulation provides no loophole. Neither agent is a DEA-controlled substance; control here runs through FDA drug law (unapproved new drug), not scheduling.

Bottom line. The tesamorelin/ipamorelin stack is mechanistically plausible and component-validated, but combination-unproven. The class principle — GHRH plus a ghrelin-receptor agonist yields a supra-additive acute GH pulse — is Grade A, yet those studies used GHRP-6/GHRP-2, not ipamorelin, and measured an acute GH spike rather than any clinical outcome. Tesamorelin alone earns Grade A in HIV lipodystrophy; ipamorelin has clean animal GH-selectivity data. What is hyped is the leap to "this exact blend improves body composition, recovery, and healthspan in healthy adults" — for which not one RCT, cohort, or open-label trial exists. Key uncertainties are the long-term IGF-1 and neoplasia risk of stacking two GH-raising agents, glucose effects, and whether real-world dosing achieves anything beyond tesamorelin monotherapy. For any tested athlete, the stack is categorically prohibited. Regulatory facts here are current as of June 2026 and should be re-verified as the rolling FDA peptide review proceeds.